Home > Insider Trading > Filing (0001638599-17-001129)

Filing Details

Accession Number:: 0001638599-17-001129
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2017-11-13 18:19:12
Reporting Period:: 2017-11-09

Accepted Time:: 2017-11-13 18:19:12
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1453687	Selecta Biosciences Inc	SELB	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1055624	A Timothy Springer	Harvard Medical School, Ctr 200 Longwood Ave. Boston MA 02115		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2017-11-09	21,100	$9.33	376,513	No	4	P	Direct
Common Stock	Acquisiton	2017-11-09	900	$9.74	377,413	No	4	P	Direct
Common Stock	Acquisiton	2017-11-09	4,900	$9.33	4,900	No	4	P	Indirect	By wife
Common Stock	Acquisiton	2017-11-09	100	$9.78	5,000	No	4	P	Indirect	By wife
Common Stock	Acquisiton	2017-11-10	21,586	$9.04	398,999	No	4	P	Direct
Common Stock	Acquisiton	2017-11-10	4,752	$9.03	403,751	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Direct
No	4	P	Direct
No	4	P	Indirect	By wife
No	4	P	Indirect	By wife
No	4	P	Direct
No	4	P	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	1,237,028	Indirect	See Footnote
Common Stock	445,576	Indirect	See Footnote

Footnotes

The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $8.72 to $9.71, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $9.72 to $9.79, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $8.75 to $9.735, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $8.85 to $9.39, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $8.83 to $9.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
LKST, Inc. is the general partner of Leukon. Timothy Springer is the president of LKST, Inc. and the managing member of TAS. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein.
Held by Leukon Investments LP ("Leukon").
Held by TAS Partners, LLC ("TAS").